help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Br...
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Esteva, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esteva, F. J.
The Oncologist, Vol. 9, Suppl 3, 4–9, June 3, 2004
© 2004 AlphaMed Press

Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer

Francisco J. Esteva

The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA

Correspondence: Francisco J. Esteva, M.D., Ph.D., Department of Breast Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 424, Houston, Texas 77030-4009, USA. Telephone: 713-792-2817; Fax: 713-745-5768; e-mail: festeva{at}mdanderson.org

The human epidermal growth factor receptor (HER, ErbB) family of receptors is considered an important therapeutic target, and various types of molecularly based small molecules, including monoclonal antibodies, protein tyrosine kinase inhibitors, and therapeutic vaccines, are in development as potential therapies for metastatic breast cancer. Trastuzumab (Herceptin®; Genentech, Inc.; South San Francisco, CA), the first approved monoclonal antibody for HER-2 (ErbB-2)-overexpressing metastatic breast cancer, provided the proof of principle that targeting specific receptors results in clinical benefit. Other monoclonal antibodies and the small molecule dual protein tyrosine kinase inhibitors show great promise as treatments for metastatic breast cancer but require evaluation in clinical trials to assess their benefits. Therapeutic vaccines may have a role, particularly in early-stage disease, but they are associated with greater limitations and study design issues that make their evaluation difficult. Optimum combination therapy regimens with a variety of novel approaches that incorporate small molecule targeted therapies need to be developed, and the population most likely to benefit from targeted therapies needs to be identified.

Key Words. Breast cancer • Monoclonal antibodies • Tyrosine kinase inhibitors • Vaccines




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
N. Harada, R. Yasunaga, Y. Higashimura, R. Yamaji, K. Fujimoto, J. Moss, H. Inui, and Y. Nakano
Glyceraldehyde-3-phosphate Dehydrogenase Enhances Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells
J. Biol. Chem., August 3, 2007; 282(31): 22651 - 22661.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
R. D. Lester, M. Jo, V. Montel, S. Takimoto, and S. L. Gonias
uPAR induces epithelial mesenchymal transition in hypoxic breast cancer cells
J. Cell Biol., July 24, 2007; 178(3): 425 - 436.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. K. Martens, K. M. Kirschner, C. Warnecke, and H. Scholz
Hypoxia-inducible Factor-1 (HIF-1) Is a Transcriptional Activator of the TrkB Neurotrophin Receptor Gene
J. Biol. Chem., May 11, 2007; 282(19): 14379 - 14388.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. W. Dewhirst, I. C. Navia, D. M. Brizel, C. Willett, and T. W. Secomb
Multiple Etiologies of Tumor Hypoxia Require Multifaceted Solutions
Clin. Cancer Res., January 15, 2007; 13(2): 375 - 377.
[Full Text] [PDF]


Home page
Ann OncolHome page
G. Curigliano, G. Spitaleri, E. Pietri, M. Rescigno, F. de Braud, A. Cardillo, E. Munzone, A. Rocca, G. Bonizzi, V. Brichard, et al.
Breast cancer vaccines: a clinical reality or fairy tale?
Ann. Onc., May 1, 2006; 17(5): 750 - 762.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. E. Hardee, M. O. Arcasoy, K. L. Blackwell, J. P. Kirkpatrick, and M. W. Dewhirst
Erythropoietin Biology in Cancer
Clin. Cancer Res., January 15, 2006; 12(2): 332 - 339.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C. A. Hudis and S. Van Belle
Introduction: Examining the Potential Impact of Anemia Treatment on Clinical Outcomes in Anemic Cancer Patients
Oncologist, November 1, 2004; 9(suppl_5): 1 - 3.
[Full Text] [PDF]


Home page
The OncologistHome page
P. Vaupel
The Role of Hypoxia-Induced Factors in Tumor Progression
Oncologist, November 1, 2004; 9(suppl_5): 10 - 17.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
F. Farrell and A. Lee
The Erythropoietin Receptor and Its Expression in Tumor Cells and Other Tissues
Oncologist, November 1, 2004; 9(suppl_5): 18 - 30.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
L. Harrison and K. Blackwell
Hypoxia and Anemia: Factors in Decreased Sensitivity to Radiation Therapy and Chemotherapy?
Oncologist, November 1, 2004; 9(suppl_5): 31 - 40.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
H. Ludwig, C. A. Hudis, G. Goss, and B. Leyland-Jones
Epoetin Alfa: Future Directions and Future Research
Oncologist, November 1, 2004; 9(suppl_5): 70 - 73.
[Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2004 by AlphaMed Press.